SCHEMBL7049832

SCHEMBL7049832

CCCCc1ncc(C[C@H](NC(=O)CCC)C(=O)O)n1Cc1ccccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7056871 0.94 PTGES (0.44) —
SCHEMBL8971489 0.94 — —
SCHEMBL8957070 0.94 — —
SCHEMBL8957067 0.94 — —
SCHEMBL8971306 0.92 — —
SCHEMBL8971896 0.91 — —
SCHEMBL8971903 0.91 — —
SCHEMBL9473826 0.90 — —
SCHEMBL8957121 0.89 AGTR1 (0.50) —
SCHEMBL8957189 0.88 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5565480-A ANGIOTENSIN II RECEPTOR ANTAGONIST; USEFUL IN REGULATING HYPERTENSION, TREATMENT OF CONGESTIVE HEART FAILURE, RENAL FAILURE AND GLUCOMA SMITHKLINE BEECHAM CORPORATION (US) 1996-10-15 — — US claimed
EP-0536262-A4 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORP (US) 1996-08-14 — — EP claimed
US-5444081-A Treatment of hypertension, congestive heart failure, renal failure, glaucoma SMITHKLINE BEECHAM CORP (US) 1995-08-22 — — US claimed
EP-0536262-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1993-04-14 — — EP claimed
WO-1992000068-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1992-01-09 — — WO claimed
US-20030187044-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-10-02 — — US disclosed
US-20030166700-A1 Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression SMITHKLINE BEECHAM P.L.C. 2003-09-04 — — US disclosed
US-20030096851-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-05-22 — — US disclosed
EP-0724387-B1 ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES SMITHKLINE BEECHAM CORP (US) 2003-05-02 — — EP disclosed
US-20030069293-A1 Medicament SMITHKLINE BEECHAM PLC 2003-04-10 — — US disclosed
US-20030050285-A1 Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke SMITHKLINE BEECHAM P.L.C. 2003-03-13 — — US disclosed
US-20030004201-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-01-02 — — US disclosed
WO-1992010186-A1 USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010184-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010183-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010097-A1 ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 1992-06-25 — — WO disclosed
WO-1992010185-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010188-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010179-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF MACULAR DEGENERATION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992000068-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1992-01-09 — — WO disclosed
Send feedback